Seventy-seven adults starting fostemsavir in US clinical practice between July 2020 and August 2023 were followed for 12 months, stratified by viral suppression at baseline. Most remained on the drug at 12 months; most suppressed initiators maintained suppression, whereas only a minority of viraemic initiators achieved it. CD4 counts rose in both subgroups, with greater gains among those suppressed at initiation.
Why it is interesting: A real-world persistence and suppression reading for a late-line HIV agent in a small cohort.
Cite this item
BibTeX
Free sign-up. A digest of the new papers twice a week, grouped by domain.